Moreover, anti-Trop2 bispecific antibody was approved to effectively lead pre-targeted immunoPET and radioimmunotherapy of PCa in preclinical models, which significantly increased PCa related survival [83,84]. Here, TACSTD2 is linked to posterior cortical atrophy.